You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.



Ask the Narcolepsy Expert: Guidance for Treatment Selection  

  • Authors: Michael J. Thorpy, MD
  • CME / ABIM MOC Released: 2/1/2023
  • Valid for credit through: 2/1/2024
Start Activity

  • Credits Available

    Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.25 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for neurologists, psychiatrists, primary care physicians, pulmonologists, and other clinicians who treat patients with narcolepsy.

The goal of this activity is for learners to be better able to recognize FDA-approved options for the management of narcolepsy, available long-term efficacy/safety data, and factors that impact patient selection for the available medications.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical data for FDA-approved therapies indicated for the management of narcolepsy
    • Clinically relevant factors that differentiate FDA-approved therapies for the management of narcolepsy


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


  • Michael J. Thorpy, MD

    Professor of Neurology
    Albert Einstein College of Medicine
    Director, Sleep-Wake Disorders Center
    Montefiore Medical Center
    Bronx, New York


    Michael J. Thorpy, MD, has the following relevant financial relationships: 
    Consultant or advisor for: Axsome Therapeutics, Inc.; Balance Therapeutics; Eisai Pharmaceuticals; Flamel/Avadel; Harmony Biosciences; Idorsia Pharmaceuticals; Jazz Pharmaceuticals; NLS Pharmaceuticals; Suven Life Sciences Ltd.; Takeda Pharmaceutical Co., Ltd; XW Pharma


  • Kathy Merlo

    Medical Education Director, Medscape, LLC 


    Kathy Merlo has no relevant financial relationships. 

  • Megan Breuer, PhD

    Medical Writer, Medscape, LLC 


    Megan Breuer, PhD, has the following relevant financial relationships:
    Consultant/advisor: Paratek Pharmaceuticals, Inc.
    Owns stock (publicly traded) in: Bristol Myers Squibb Company, Johnson & Johnson, Paratek Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Ask the Narcolepsy Expert: Guidance for Treatment Selection  

Authors: Michael J. Thorpy, MDFaculty and Disclosures

CME / ABIM MOC Released: 2/1/2023

Valid for credit through: 2/1/2024



  1. Golden EC, et al. Narcolepsy: diagnosis and management. Cleve Clin Gen Med. 2018;85:959-969.
  2. Basetti, CLA, et al. Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat Rev Neurol. 2019;15:519-539.
  3. Thorpy MJ, et al. Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications. Sleep Med. 2020;68:97-109.
  4. de Biase S, et al. Evaluating pitolisant as a narcolepsy treatment option. Expert Opin Pharmacother. 2021;22:155-162.
  5. Maski K, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17:1881-1893.
  6. Barateau L, et al. Recent advances in treatment for narcolepsy. Ther Adv Neurol Disord. 2019;12:1756286419875622.
  7. Thorpy MJ, et al. Clinical and practical considerations in the pharmacologic management of narcolepsy. Sleep Med. 2015;16:9-18.
  8. Thorpy MJ. Recently approved and upcoming treatments for narcolepsy. CNS Drugs. 2020;34:9-27.
  9. Abad VC. An evaluation of sodium oxybate as a treatment option for narcolepsy. Expert Opin Pharmacother. 2019;20:1189-1199.
  10. Bogan RK, et al. Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy. Sleep. 2021;44:zsaa206.
  11. Dauvilliers Y, et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013;12:1068-1075.
  12. Fabara SP, et al. Efficacy of pitolisant on the treatment of narcolepsy: a systematic review. Cureus. 2021;13:e16095.
  13. Iturburu A, et al. Solriamfetol for the use of narcolepsy: a systematic review. Cureus. 2022;14:e24937.
« Return to: Ask the Narcolepsy Expert: Guidance for Treatment Selection  
  • Print